This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 May 2011

Frontage & BSPC Receive FDA Approval for Generic Norvasc

With this approval, BSPC will become the first Chinese-owned pharma firm to be able to launch an FDA-approved oral solid dose product on the U.S. market.

Beijing Second Pharmaceutical Co., Ltd. (BSPC), a China-based generic pharmaceutical company, has received FDA approval of its ANDA 090752 for Amlodipine Besylate, a generic form of Pfizer’s Norvasc.

 

With this approval, BSPC will become the first Chinese-owned pharma firm to be able to launch an FDA-approved oral solid dose product on the U.S. market.

 

Working with BSPC, Frontage Laboratories, Inc. developed the generic-equivalent formulation and analytical methodologies, provided GMP training and facilities commissioning services, performed technical transfer and scale-up of the developed formulation process, assisted in the execution of the submission batch manufacturing, executed the bioequivalence study, and compiled the electron

Related News